Nuvaring News

Women in the United States who have experienced a PE or DVT are considering becoming part of a Nuvaring class action lawsuit.

Significant questions of late have arisen with regards to the Nuvaring labels. Concern is that sufficient notice has not been provided that warns women of the risk of pulmonary embolism (PE), deep vein thrombosis (DVT) and additional related health conditions including stroke. As follows, a press release provided by the Office of Public Health and Science emphasizes blood clots and their potential for life-threatening risks.

A Call to Action is issued to Prevent Pulmonary Embolism and Deep Vein Thrombosis

Steven K. Galson, M.D., M.P.H., is Acting Surgeon General. He today put forth a Call to Action to decrease the number of medical cases involving pulmonary embolism and deep vein thrombosis across the United States.

Galson encouraged every American to educate themselves and avert such treatable conditions.

Pulmonary embolism and deep vein thrombosis impact some 350,000 to 600,000 Americans every year. It is anticipated that those numbers will rise as the population ages. Combined, pulmonary embolism and deep vein thrombosis are accountable for more than 100,000 deaths every year.

A blood clot that is within a deep vein, typically in the thigh or lower leg, is deep vein thrombosis. Such a clot can restrict blood and create skin discoloration, swelling and pain. In the most severe cases, this condition can cause a pulmonary embolism. This occurs when a portion of the blood clot falls loose and moves via the bloodstream into the lungs. The clot can then block an artery of a lung, thus damaging the lungs or additional vital organs as a result of lost oxygen.

Galson stated that pulmonary embolism and deep vein thrombosis both are typically “silent” conditions. Either can happen without symptoms, taking patients unaware. He further indicated that much progress have been made in understanding the disorders. Medical professionals now have knowledge on preventing, diagnosing and treating them. Such knowledge needs to be put “into action.”

Researchers have discovered that with a number of cases, pulmonary embolism and deep vein thrombosis occur in persons with an inherited disorder that inhibits blood clotting. Additional risk factors also exist, as do events that simply trigger the conditions.

Galson indicated that hospitalization, bed rest confinement, undergoing major surgery, traumatic occurrences, and traveling for multiple hours can add to a person’s chances of developing pulmonary embolism and deep vein thrombosis. He and other medical professionals desire to increase peoples’ awareness and knowledge of such life-threatening conditions. They also wish to encourage both patients and health care professional to act in ways that “prevent them.”

The Call to Action encourages a comprehensive and multifaceted strategy to decrease nationwide the amount of cases of pulmonary embolism and deep vein thrombosis. The strategy stresses the need for:

• Heightened awareness regarding pulmonary embolism and deep vein thrombosis.
• Verification-based treatments for deep vein thrombosis.
• Increased research for the sources, deterrence and therapy of deep vein thrombosis.

A Surgeon General’s Workshop on Deep Vein Thrombosis resulted in the Call to Action. The workshop assembled in May, 2006. The National Heart, Lung, and Blood Institute (NHLBI) co-sponsored the workshop.

Elizabeth G. Nabel, M.D. is the Director of the NHLBI. She noted that pulmonary embolism and deep vein thrombosis both are significant public health dilemmas. The NHLBI has pledged to further support all research efforts that advance peoples’ comprehension of the debilitating and life-threatening risks posed by such conditions. She added that new research helps bring to the forefront those factors that heighten a person’s risk for getting precarious blood clots. Medical professionals and experts of public health must collaborate to utilize scientific evidence “to save lives.”

The Call to Action was contributed to by The Agency for Healthcare Research and Quality (AHRQ) by releasing two new informative guides that explain preventive measures for precarious blood clots. One guide is aimed at patients, and the other is for providers of health care. Carolyn M. Clancy, M.D., is the Director for the AHRQ. She indicated that fighting the conditions of pulmonary embolism and deep vein thrombosis requires team efforts. Patients and providers of health care must work alike.

We are representatives of all women who suffer Nuvaring side effects. We work on the basis of a contingency, meaning no legal fees are paid unless your case wins compensations. Please call our toll free number for a free no-obligation consultation. You can also complete a short contact form available online, and a Nuvaring class action lawsuit attorney will contact you. We are available to provide answers to all of your questions.